Retinal degeneration is a leading cause of incurable low vision and blindness affecting about 200 million worldwide. The pathologies include inherited retinitis pigmentosa (RP), age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME) and other damages to the eye/retina. Despite recent therapeutic advances for retinal diseases the real-world results of treatment are poor, and there are no or only limited treatment options in many areas, resulting in an overall high unmet need. One of the major challenges of such treatments is inability to deliver the therapy to the right place with the right dosage. This lead to ineffective treatment and results into multiple re-visits to the doctor for repeat treatment and poise side effects like IOP and glaucoma resulting in worsening the condition.
EIS is a novel delivery system for delivery of advanced retinal therapies into the back of the eye. The device encompasses a minimally-invasive injector and a fixation tool, featuring a unique access method through the suprachoroidal space and the matrix between the choroidal blood vessels. It is an effective retinal delivery method with wide drug distribution over 80% which leads to minimal surgeries needed for treatment.
Identifying the need, Everads developed the safe, minimally invasive and effective device to deliver targeted therapy, potentially improving the clinical outcome. The EIS delivery system has minimal side effects and will drastically improve patient's quality of life. It allows the patients who often tend to be elderly be more independent. Everads Therapy thus envisions a future where safer and effective therapy delivery techniques will enable better outcomes for retinal degeneration treatment.
The overall objectives of the project include, defining a minimum viable product, establish a feasible product development plan and industrialisation strategy, plan demonstration and validation trials and analyse risks and opportunities.
